Developing Substrate Replacement Therapies
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. Its lead program, GLM101, is currently in clinical trials in the US and Europe and has received Orphan Drug Designation (ODD) in the US and Europe and Rare Paediatric Disease Designation (RPDD) in the US.
CEO Steven Axon
Advent Contact Dominic Schmidt
Advent invested in 2024.
Private Companies
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
Press Release. Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG GLM101 is the first disease-modifying…
Read More
